Project/Area Number |
17K15025
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | Okayama University |
Principal Investigator |
|
Research Collaborator |
UDONO Heiichiro
EIKAWA Shingo
|
Project Period (FY) |
2017-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | Treg / メトホルミン / 代謝 / 制御性T細胞(Treg) / がん免疫 / 制御性T細胞(Treg) / 癌 / 腫瘍免疫 / 制御性T細胞 |
Outline of Final Research Achievements |
We have already demonstrated that the type 2 diabetes drug metformin has antitumor activity via immune cells. In this study, we analyzed the effect of metformin on immunoregulatory regulatory T cells (Tregs), which are said to contribute to tumor growth. In the mouse tumor transplantation model, we observed that administration of metformin induced Treg apoptosis and suppressed Treg function in only tumor local sites. In addition, we demonstrated that the metabolism of Treg, which metabolism is dominant in fatty acid oxidation, is predominantly changed from fatty acid oxidation to glycolytic metabolism at the time of differentiation / induction from non-Treg cells to Treg.
|
Academic Significance and Societal Importance of the Research Achievements |
メトホルミンは世界中で使用されている糖尿病薬であり、安全性や実用性が高い。また、その費用も安価である。さらに、全身のTregには影響を与えず、腫瘍局所のみに作用することを明らかとしており、自己免疫疾患の副作用が生じにくいえ、非常に革新的である。腫瘍内Tregのみを制御する薬剤の報告は未だになかったため、本研究での結果は学術的にも社会的にも非常に高いといえる。
|